Research programme: histone and peptide based therapeutics - SymbioTec
Alternative Names: rhH1 x; rhH1.xLatest Information Update: 25 Jan 2012
Price :
$50 *
At a glance
- Originator SymbioTec
- Class Peptides; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jan 2012 SymbioTec has been acquired by Xenetic Biosciences
- 09 Jul 2010 No development reported - Preclinical for Cancer in Germany (unspecified route)
- 24 Apr 2007 Preclinical trials in Acute myeloid leukaemia in Germany (unspecified route)